Clinical trialPhase 2Completed
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- August 2014
- Expected end
- August 2016
- Enrollment
- 14 participants
- Sites
- 1
- Primary outcomes
- Overall Response Rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 September 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Detailed description public domain (ClinicalTrials.gov)
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors in adult patients age \>/= to 18.